Somatostatin Receptor Type 4 – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Somatostatin Receptor Type 4 (SSTR4)- Pipeline Review, H2 2019’, provides in depth analysis on Somatostatin Receptor Type 4 (SSTR4) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Hormonal Disorders, Central Nervous System, Metabolic Disorders and Oncology under development targeting Somatostatin Receptor Type 4 (SSTR4).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for Somatostatin Receptor Type 4 (SSTR4)

– The report reviews Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics and enlists all their major and minor projects

– The report assesses Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Somatostatin Receptor Type 4 (SSTR4)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Somatostatin Receptor Type 4 (SSTR4) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“Eli Lilly and Co

GlyTech Inc

Peptide Logic LLC

Strongbridge Biopharma plc”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Somatostatin Receptor Type 4 (SSTR4) Overview

Somatostatin Receptor Type 4 (SSTR4) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Somatostatin Receptor Type 4 (SSTR4) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Somatostatin Receptor Type 4 (SSTR4) Companies Involved in Therapeutics Development

Centrexion Therapeutics Corp

Crinetics Pharmaceuticals Inc

Strongbridge Biopharma plc

Somatostatin Receptor Type 4 (SSTR4) Drug Profiles

CNTX-0290 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize SSTR4 for Chronic Pain and Neuropathic Pain Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize SSTR2 and SSTR4 for Chronic Pain and Neuropathic Pain Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Agonize Somatostatin Receptors for Acromegaly Drug Profile

Product Description

Mechanism Of Action

R&D Progress

veldoreotide Drug Profile

Product Description

Mechanism Of Action

R&D Progress

veldoreotide MR Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Somatostatin Receptor Type 4 (SSTR4) Dormant Products

Somatostatin Receptor Type 4 (SSTR4) Product Development Milestones

Featured News & Press Releases

Jul 18, 2017: Centrexion Provides Pipeline Updates, Plans for Phase 2 Study of Pain Drug Candidate CNTX-0290

May 31, 2016: Strongbridge Biopharma plc Announces Presentation of COR-005 Data at the European Congress of Endocrinology

Apr 27, 2015: Crinetics Pharmaceuticals Awarded NIH Fast-Track Grant to Develop Somatostatin Receptor Agonist Drugs for Chronic Pain

Apr 22, 2014: Aspireo Reports Data in Further Phase Ib Study

Sep 25, 2013: FDA Grants Orphan Drug Designation for Aspireo’s Somatoprim

Jun 18, 2013: Aspireo Reports Start of Further Phase I Study in Healthy Volunteers

Apr 03, 2013: Aspireo Pharma Reports Somatoprim Phase IIa Proof Of Concept Results In Acromegaly

Jan 07, 2013: Aspireo Pharma Reports Phase Ib Interim Data For Somatoprim

Nov 26, 2012: Aspireo Pharma Announces EMA's Committee For Orphan Medicinal Products Recommends Orphan Medicinal Product Designation For Somatoprim

Nov 06, 2012: Aspireo Pharma Starts Somatoprim Phase IIa Study In Acromegaly Patients

Sep 28, 2012: Evotec And Aspireo Pharma Enter Into Strategic Advisory Agreement For Somatoprim

Jun 26, 2012: Somatoprim is a potent agonist of Somatostatin Receptors 2 and 5

Apr 05, 2012: Aspireo Starts Phase I Multi Ascending Dose Study with Somatoprim

Feb 26, 2009: DeveloGen Reports Positive Phase I Clinical Trial Results for DG3173

Oct 08, 2008: DeveloGen Announces Completion Of A Phase I Clinical Trial Of DG3173, A Novel Somatostatin Analogue For The Treatment Of Acromegaly

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indication, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Eli Lilly and Co, H2 2019

Pipeline by GlyTech Inc, H2 2019

Pipeline by Peptide Logic LLC, H2 2019

Pipeline by Strongbridge Biopharma plc, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019

Dormant Products, H2 2019 (Contd..2), H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports